Adjuvant-dependent effects on the safety and efficacy of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Heise M, Dillard J, Taft-Benz S, Knight A, Anderson E, Pressey K, Parotti B, Martinez S, Diaz J, Sarkar S, Madden E, De la Cruz G, Adams L, Dinnon K 3rd, Leist S, Martinez D, Schaefer A, Powers J, Yount B, Castillo I, Morales N, Burdick J, Evangelista MK, Ralph L, Pankow N, Linnertz C, Lakshmanane P, Montgomery S, Ferris M, Baric R, Baxter V.
Heise M, et al. Among authors: sarkar s.
Res Sq [Preprint]. 2023 Oct 27:rs.3.rs-3401539. doi: 10.21203/rs.3.rs-3401539/v1.
Res Sq. 2023.
PMID: 37961507
Free PMC article.
Updated.
Preprint.